IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Nir Hacohen, Qian Huang and Dongyu Liu

Application No.:

10/085,982

Group Art Unit:

1645

Filed:

October 24, 2001

Examiner:

Not Assigned

Title:

Response of Dendritic Cells to a Diverse Set of Pathogens

## CERTIFICATE OF MAILING

Thereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, P.O. Box

2327, Arlington, VA 22202 on \$11,211,42

Typed or printed name of person signing certificate

RECEIVED

AUG 2 0 2002

INFORMATION DISCLOSURE STATEMENT

TECH CENTER 1600/2900

Assistant Commissioner for Patents P.O. Box 2327 Arlington, VA 22202

Sir:

This Information Disclosure Statement is submitted
--

[ ] under 37 CFR 1.129(a), or

(First/Second submission after Final Rejection)

[X] under 37 CFR 1.97(b), or

(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

under 37 CFR 1.97(c) together with either:

[ ] a Statement under 37 CFR 1.97(e), as checked below, or

[ ] a \$180.00 fee under 37 CFR 1.17(p), or

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

[ ] under 37 CFR 1.97(d) together with:

a Statement under 37 CFR 1.97(e), as checked below, and

a \$180.00 fee under 37 CFR 1.17(p), or

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

[ ] under 37 CFR 1.97(i):

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

(Filed after payment of issue fee)

[ ] Each item of information contained in this Information Disclosure Statement was first cited in								
any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or								
No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.								
Statement Under 37 CFR 1.704(d) (Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 200								
[ ] Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.								
[X] Enclosed herewith is form PTO-1449:								
[X] Copies of the cited references (AR-AR3) are enclosed.								
Copies of cited references are enclosed except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]								
[ ] The listed references were cited in the enclosed International Search Report in a counterpart foreign application.								
The "concise explanation" requirement (non-English references) for reference(s) [ under 37 CFR 1.98(a)(3) is satisfied by:								
[ ] the explanation provided on the attached sheet.								
[ ] the explanation provided in the Specification.								
[ ] submission of the enclosed International Search Report.								
[ ] submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.								
[ ] the enclosed English language abstract.								

[ ]	Applio	cant requests that the following n	on-published pending applic	cations be considered:						
Examiner' Initials	s									
	-	U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]						
	-	U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]						
	-	U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]						
		Examiner	Date	-						
	[ ]	A copy of each above-cited app	olication, including the curre	nt claims, is enclosed.						
	[ ]	A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed.								
The E refere	xamine nces we	r is requested to return a copy of ere considered with the next offic	the above list of pending apper communication.	plications indicating which						
It is re	equested	I that the information disclosed h	erein be made of record in the	nis application.						
Metho	od of pa	yment:								
[ ]		eck for the fee noted above is enclosed, or the fee has been included in the check with the npanying Reply. A copy of this Statement is enclosed.								
[ ]	Please enclos	the charge Deposit Account 08-0380 in the amount of \$[ ]. A copy of this Statement is used.								
[X]	Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-038									
			Respectfully submitted, HAMILTON, BROOK, SMI	TH & REYNOLDS, P.C.						
		F	Lisa M. Treannie Registration No.: 41,368 Telephone: (978) 341-0036 Facsimile: (978) 341-0136							

Concord, MA 01742-9133 Dated: 8/9/07—

EXAMINER

DATE CONSIDERED

Immunol., 164:3596-3599 (2000).

Dendritic Cells Results in the Inhibition of T Cell Proliferation," J.

PTO 1449 REPRODUCED  INFORMATION DISCLOSURE CITATION  IN AN APPLICATION  May 28, 2002				ATTORNEY DOCKET NO. 2825.2019-001	APPLICATION NO. 10/085,982							
				APPLICANTS Nir Hacohen, et al.		Alis	1 6 2002	3C 98				
(Use several sheets if necessary)				FILING DATE October 24, 2001	GROUP 1645	THE STATE OF THE S	THE CONTRACTOR					
U.S. PATENT DOCUMENTS												
EXAM - INER INI - TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE					
	L											
	,		FOREIG	N PATENT DOCUMENTS		<del></del>	ı					
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSL YES	ATION ON				
	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)											
	AT2/											
	AU2	marphy of and savirious, of, respectively and sorrespond to the saving										
	AV2	O'Reilly, L. and Strasser, A., "Apoptosis and Autoimmune Disease," Inflamm. Res., 48:5-21(1999).										
	AW2	Rescigno, M. et al., "Bacteria-induced Neo-biosynthesis, Stabilization, and Surface Expression of Functional Class I Molecules in Mouse Dendritic Cells," Proc. Natl. Acad. Sci. U.S.A., 95:5229-5234 (1998).										
	AX2	Rissoan, M. et al., "Reciprocal Control of T Helper Cell and Dendritic Cell Differentiation," Science, 283:1183-1186 (1999).										
	AY2	Tomasec, P. et al., "Surface Expression of HLA-E, an Inhibitor of Natural Killer Cells, Enhanced by Human Cytomegalovirus gpUL40," Science, 287:1031-1033 (2000).										
	AZ	von Andrian, U. and Mackay, C., "T-Cell Function and Migration: Two Sides of the Same Coin," New Engl. J. Med., 343(14):1020-1034 (2000).										
	AR3	Wenger, R., "Mammalian Oxygen Sensing, Signalling and Gene Regulation," J. Exp. Biol., 203:1253-1263 (2000).										
EXAMII	EXAMINER DATE CONSIDERED											

RECEIVED

AUG 2 0 2002

TECH CENTER 1600/2900